5466-43-3

Basic information

• Product Name: 2,4-DICHLORO-6,7-DIHYDRO-5H-CYCLOPENTAPYRIMIDINE
• Synonyms: 2,4-DICHLORO-6,7-DIHYDRO-5H-CYCLOPENTAPYRIMIDINE;2,4-Dichloro-5H,6H,7H-cyclopenta[d]pyrimidine;2,4-Dichloro-5,6-trimethylenepyrimidine;4-dichloro-6;7-dihydro-5H-cyclopenta[d]pyriMidine;2,4-dichloro-6,7-dihydro-5H-cyclopenta[d][1,3]chlorazine;EOS-60937
• CAS NO: 5466-43-3
• Molecular Formula: C₇H₆Cl₂N₂
• Molecular Weight: 189.05
• Product Categories: Heterocycle-Pyrimidine series
• Mol File: 5466-43-3.mol

Chemical Properties

• Melting Point: 70-72℃
• Boiling Point: 307℃
• Flash Point: 168℃
• Appearance: /
• Density: 1.466
• Vapor Pressure: 0.00137mmHg at 25°C
• Refractive Index: 1.605
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -1.78±0.20(Predicted)
• CAS DataBase Reference: 2,4-DICHLORO-6,7-DIHYDRO-5H-CYCLOPENTAPYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-DICHLORO-6,7-DIHYDRO-5H-CYCLOPENTAPYRIMIDINE(5466-43-3)
• EPA Substance Registry System: 2,4-DICHLORO-6,7-DIHYDRO-5H-CYCLOPENTAPYRIMIDINE(5466-43-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 5466-43-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
2,4-Dichloro-6,7-dihydro-5H-cyclopentapyrimidine is used as a chemical intermediate for the synthesis of new pharmaceutical substances. Its pyrimidine backbone makes it a promising candidate for the development of potential drugs.
Used in Chemical Synthesis:
2,4-Dichloro-6,7-dihydro-5H-cyclopentapyrimidine is used as a building block in the synthesis of various organic compounds. Its unique structure allows for the creation of new molecules with potential applications in different industries.
Used in Research:
2,4-Dichloro-6,7-dihydro-5H-cyclopentapyrimidine is used as a subject of study in chemical research to better understand its properties, reactivity, and potential applications. This knowledge can contribute to the development of new substances and technologies.

InChI:InChI=1/C7H6Cl2N2/c8-6-4-2-1-3-5(4)10-7(9)11-6/h1-3H2

Upstream product

• 5466-00-2 6,7-dihydro-5H-cyclopenta[d]pyrimidine-2,4-diol 
• 10472-24-9 methyl 2-oxocyclopentane-1-carboxylate 
• 57-13-6 urea 
• 76-05-1 trifluoroacetic acid 
• 1196101-51-5 methyl 2-ureidocyclopentene-1-carboxylate 
• 3087-14-7 2-(methylthio)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-ol 
• 5466-00-2 1,5,6,7-tetrahydro-cyclopentapyrimidine-2,4-dione 
• 611-10-9 2-ethoxycarbonyl-1-cyclopentanone 
• 18227-09-3 2-ureido-1-carbethoxycyclopent-1-ene 

Downstream Products

• 76780-99-9 2-chloro-4-morpholin-4-yl-6,7-dihydro-5H-cyclopentapyrimidine 
• 81532-49-2 4-Butoxy-2-chloro-6,7-dihydro-5H-cyclopentapyrimidine 
• 81532-47-0 2-Chloro-4-methoxy-6,7-dihydro-5H-cyclopentapyrimidine 
• 78042-66-7 2-Chloro-4-ethoxy-6,7-dihydro-5H-cyclopentapyrimidine 
• 81532-48-1 2-Chloro-4-isopropoxy-6,7-dihydro-5H-cyclopentapyrimidine 
• 76780-98-8 2-chloro-N-methyl-5H,6H,7H-cyclopenta[d]pyrimidin-4-amine 
• 81532-50-5 2-chloro-4-phenoxy-5,6-trimethylenepyrimidine 
• 76780-97-7 (2-chloro-6,7-dihydro-5H-cyclopentapyrimidin-4-yl)amine 
• 259680-54-1 2-chloro-N-pentyl-6,7-dihydro-5H-cyclopenta[d]pyrimidine-4-amine 
• 58170-96-0 2-chloro-4-phenyl-6,7-dihydro-5H-cyclopentapyrimidine 
• 1215017-92-7 tert-butyl-(2-chloro-6,7-dihydro-5H-cyclopentapyrimidin-4-yl)-amine 
• 1215018-07-7 2-chloro-4-(3,5-dimethyl-isoxazol-4-yl)-6,7-dihydro-5H-cyclopentapyrimidine 
• 1215017-86-9 1-[4-(2-chloro-6,7-dihydro-5H-cyclopentapyrimidin-4-ylamino)-phenyl]-cyclobutanecarboxylic acid methyl ester 
• 1616083-88-5 (R)-1-(4-(5-isopropyl-1H-pyrazol-3-ylamino)-6,7-dihydro-5H-cyclopenta[d]pyrimidin-2-yl)-N-methylpyrrolidine-2-carboxamide 

Relevant articles and documents

Methylpyrazole derivatives as RET inhibitor

The invention relates to a methylpyrazole derivative as an RET inhibitor, in particular to a compound as shown in a formula (I), a stereoisomer and pharmaceutically acceptable salt thereof, a preparation method and a pharmaceutical composition thereof. The compound of the formula (I) can be used for preventing or treating diseases mediated by abnormal RET activity.

METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS

The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.

Matrix Metalloproteinase 13 Inhibitors for Modulation of Osteoclastogenesis: Enhancement of Solubility and Stability

Matrix metalloproteinase 13 (MMP-13) activity has been correlated to breast cancer bone metastasis. It has been proposed that MMP-13 contributes to bone metastasis through the promotion of osteoclastogenesis. To explore the mechanisms of MMP-13 action, we previously described a highly efficacious and selective MMP-13 inhibitor, RF036. Unfortunately, further pursuit of RF036 as a probe of MMP-13 in vitro and in vivo activities was not practical due to the limited solubility and stability of the inhibitor. Our new study has explored replacing the RF036 backbone sulfur atom and terminal methyl group to create inhibitors with more favorable pharmacokinetic properties. One compound, designated inhibitor 3, in which the backbone sulfur and terminal methyl group of RF036 were replaced by nitrogen and oxetane, respectively, had comparable activity, selectivity, and membrane permeability to RF036, while exhibiting greatly enhanced solubility and stability. Inhibitor 3 effectively inhibited MMP-13-mediated osteoclastogenesis but spared collagenolysis, and thus represents a next-generation MMP-13 probe applicable for in vivo studies of breast cancer metastasis.

Discovery of novel pyrimidine molecules containing boronic acid as VCP/p97 Inhibitors

Valine-containing protein (VCP) is a member of the adenosine triphosphate family involved in a variety of cellular activities. VCP/p97 is capable of maintaining protein homeostasis and mediating the degradation of misfolded polypeptides by the ubiquitin–proteasome system (UPS). In this manuscript, a series of novel p97 inhibitors with pyrimidine as core structure were designed, synthesized and biologically evaluated. Based on the enzymatic results, a detailed structure–activity relationship discussion of the synthesized compounds was carried out. Furthermore, cellular activities of the compounds with enzymatic potency of less than 200 nM were investigated by using A549 and RPMI8226 cell lines. Among the screened inhibitors, compound 17 (IC50, 54.7 nM) showed good enzymatic activity. Investigation of cellular activities with non-small cell lung cancer A549 and multiple myeloma (MM) RPMI8226 further confirmed the potency of 17 with the IC50 values of 2.80 μM and 0.86 μM, respectively. Compound 17 is now being developed as a candidate. Finally, docking studies were carried out to explore the possible binding mode between the active inhibitor 17 and p97.

Synthesis and evaluation of novel fused pyrimidine derivatives as GPR119 agonists

A novel series of fused pyrimidine derivatives were designed, synthesized and evaluated as GPR119 agonists. Among them, cyclohexene fused compounds (tetrahydroquinazolines) showed greater GPR119 agonistic activities than did dihydrocyclopentapyrimidine and tetrahydropyridopyrimidine scaffolds. Analogues (16, 19, 26, 28, 42) bearing endo-N-Boc-nortropane amine and fluoro-substituted aniline exhibited better EC50 values (0.27–1.2 μM) though they appeared to be partial agonists.

Octahydropyrrolo[3,4-c]pyrrole derivatives and use thereof

The invention relates to octahydropyrrolo[3,4-c]pyrrole derivatives and a use thereof. The above compounds and a medicinal composition containing the compounds are used for suppressing an orexin receptor. The invention also relates to a method for preparing the compounds and the medicinal composition, and the use of the compounds and the medicinal composition in the treatment or prevention of orexin receptor related diseases.

Pyrimidine derivatives, preparation method therefor and application of pyrimidine derivatives

The invention belongs to the field of drug synthesis and relates to novel pyrimidine derivatives, pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof, preparation methods of thenovel pyrimidine derivatives and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof and use of the novel pyrimidine derivatives and the pharmaceutically acceptable salts, hydrates, solvates or prodrugs thereof in preparation of therapeutic agents, particularly PAK inhibitors. The derivatives disclosed by the invention are represented by a general formula (I) or (II), wherein each substituent is as defined in claims.

BIARYL DERIVATIVE AS GPR120 AGONIST

The present invention relates to a biaryl derivative expressed by the chemical formula 1, a method for producing the biaryl derivative, a pharmaceutical composition comprising same, and use of same, the biaryl derivative expressed by the chemical formula 1, as a GPR120 agonist, promoting GLP-1 generation in the gastro-intestinal tract, reducing insulin resistance in the liver, muscles and the like from anti-inflammatory activity in the macrophage, pancreatic cells and the like, and allowing effective use in prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Pyrimido-saturated fatty cyclodiamine compound and application thereof

The inventor of the invention designs and synthesizes a pyrimido-saturated fatty cyclodiamine compound of a brandnew structure. Tests show that most of compounds in the pyrimido-saturated fatty cyclodiamine compound disclosed by the invention have good inhibitory activity on three target spots, namely spleen tyrosine kinase (Syk), a stem cell receptor c-Kit and a platelet-derived growth factor (PDGFR-alpha); and a part of compounds show relatively good inhibitory activity in proliferation activity inhibitory experiments for synovial cells and mast cells related to inflammation and can effectively inhibit secretion of inflammatory cytokines IL-6, MMP-3 and TNF-alpha in corresponding cells and show relatively good anti-rheumatoid arthritis (RA) pharmaceutical effect. The pyrimido-saturated fat cyclodiamine compound lays a structure foundation for further design and development of a novel anti-RA medicine in future.

BICYCLIC DERIVATIVE CONTAINING PYRIMIDINE RING, AND PREPARATION METHOD THEREFOR

The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-HT4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like.